Northwestern University Feinberg School of Medicine

James Laboratory

Publications

2017

Wainwright DA, Horbinski C, Hashizume R, James CD. 2017. Therapeutic hypothesis testing with rodent brain tumor models. Neurotherapeutics. In Press.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM2, Kelleher NL, James CD, Shilatifard A. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Feb 27. doi: 10.1038/nm.4296. [Epub ahead of print]

2016

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss WA, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA. BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res. May 23 2016. pii: clincanres.1101.2015. [Epub ahead of print]. PubMed PMID: 27217440

Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in GlioblastomaCancer Cell. 29(4):563-73, Apr 11 2016. PubMed PMID: 27070703

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaJ Neurooncol. 126(3):395, Feb 2016. PubMed PMID: 26782702

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 126(3):385-93, Feb 2016. Erratum in: J Neurooncol. 126(3):395, Feb 2016. PubMed PMID: 26384810

2015

Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res. 75(24):5355-66, Dec 15 2015. PubMed PMID: 26573800

Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 6(26):21993-2005, Sep 8 2015. PubMed PMID: 26023796

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 18(9):1236-46, Sep 2015. PubMed PMID: 26258683

Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, Li Z, Xie B, Gao WQ, Sarkaria JN, Raizer JJ, James CD, Parsa AT, Hu B, Cheng SY. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α. Neuro Oncol. 17(6):832-42, Jun 2015. PubMed PMID: 25468898

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 29(7):732-45, Apr 1, 2015. PubMed PMID: 25838542

Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One. 2015 Feb 6;10(2):e0117781. doi: 10.1371/journal.pone.0117781. eCollection 2015. PubMed PMID: 25658924

2014

Nathanson DA, Gini B, Mottahedeh J, Visnyeis K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao N, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, and Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 343:72-6, 2014. PubMed PMID: 24310612

Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, and Haas-Kogan DA. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology. 16: 352-360, 2014. PubMed PMID: 24305702

Fousse SD, Nakamura JL, James CD, Chang S, and Costello JF. Response of primary glioblastoma cells to therapy is patient-specific and independent of the cancer stem cell phenotype. Neuro-Oncology. 16: 361-71, 2014. PubMed PMID: 2431163

Oh T, Fakurnejad S, Sayegh ET, Clark AJ, Ivan ME, Sun MZ, Safaee M, Bloch O, James CD, Parsa AT. Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med. 12:107, 2014. PubMed PMID: 24779345

Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014 May;16(5):628-36. doi: 10.1093/neuonc/nou025. Epub 2014 Apr 2. PubMed PMID: 24696499.

2013

Silber J, Hashizume R, Felix T, Hariano S, Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, and Gupta N. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro-Oncology. 15: 83-90, 2013. PubMed PMID: 23172372

Chen P-Y, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei K-C, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, and James CD. Comparing Routes of Delivery for Nanoliposomal Irinotecan Shows Superior Anti-Tumor Activity of Local Administration in Treating Intracranial Glioblastoma Xenografts. Neuro-Oncology. 15: 189-97, 2013. PubMed PMID: 23262509

James CD. Aberrant miRNA expression in brain tumors: a subject attracting an increasing amount of attention. Neuro-Oncology. 15:405, 2013. PubMed PMID: 23530133.

Wade A, Robinson AE, Engler JR, Petritsch C, James CD, and Phillips JJ. Proteoglycans and Their Roles in brain Cancer. FEBS Journal. 280:2399-417, 2013. PubMed PMID: 23281850.

Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expressionGenes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19. PubMed PMID: 23603901.

Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patientsCancer Discov. 2013 May;3(5):534-47. doi: 10.1158/2159-8290.CD-12-0502. Epub 2013 Mar 26. PubMed PMID: 23533263.

Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapiesClin Cancer Res. 2013 Jul 1;19(13):3681-92. doi:10.1158/1078-0432.CCR-12-3635. Epub 2013 May 17. PubMed PMID: 23685835.

Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor modelsNanomedicine (Lond). 2013 Dec;8(12):1913-25. doi: 10.2217/nnm.12.209. Epub 2013 Apr 30. PubMed PMID: 23631502.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. The mTOR kinase  inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasClin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12. PubMed PMID: 24030701.

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D,  James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancerNat Genet. 2013 Dec;45(12):1428-30. doi: 10.1038/ng.2800. Epub 2013 Oct 13. PubMed PMID: 24121789.

Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013 Dec 1;19(23):6473-83. doi: 10.1158/1078-0432.CCR-13-1121. Epub 2013 Oct 29. PubMed PMID: 24170543.

2012

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb;15(2):189-97. doi: 10.1093/neuonc/nos305. Epub 2012 Dec 21. PubMed PMID: 23262509.

Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, Gupta N. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol. 2013 Jan;15(1):83-90. doi: 10.1093/neuonc/nos281. Epub 2012 Nov 21. PubMed PMID: 23172372.

Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012 Dec;110(3):305-13. doi: 10.1007/s11060-012-0973-6. Epub 2012 Sep 17. PubMed PMID: 22983601.

Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012;7(8):e43339. doi: 10.1371/journal.pone.0043339. Epub 2012 Aug 22. PubMed PMID: 22937035.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13. PubMed PMID: 22891331.

Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman MA, Jan YN, Jan LY. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 2012 Aug 15;26(16):1780-96. doi: 10.1101/gad.193789.112. Epub 2012 Aug 1. PubMed PMID: 22855790.

Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul;70(1):33-9. doi: 10.1002/mrm.24434. Epub 2012 Jul 31. PubMed PMID: 22851374.

Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant gliomaProc Natl Acad Sci U S A. 2012 Jul 31;109(31):12722-7. doi: 10.1073/pnas.1202492109. Epub 2012 Jul 16. PubMed PMID: 22802621.

Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug;14(8):1050-61. doi: 10.1093/neuonc/nos126. Epub 2012 Jun 4. PubMed PMID: 22670012.

Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012 May 29;109(22):8710-5. doi: 10.1073/pnas.1117255109. Epub 2012 May 14. PubMed PMID: 22586120.

Toussaint LG 3rd, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol Cancer. 2012 May 14;11:32. doi: 10.1186/1476-4598-11-32. PubMed PMID: 22583806.

James CD. Nanoparticles for treating brain tumors: unlimited possibilities. Neuro Oncol. 2012 Apr;14(4):389. doi: 10.1093/neuonc/nos075. PubMed PMID: 22436865.

Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev. 2012 May 15;64(7):590-7. doi: 10.1016/j.addr.2012.01.004. Epub 2012 Jan 26. Review. PubMed PMID: 22306489.

Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neurooncol. 2012 May;108(1):29-35. doi: 10.1007/s11060-011-0796-x. Epub 2012 Jan 10. PubMed PMID: 22231932.

Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol. 2012 Jan;71(1):83-9. doi: 10.1097/NEN.0b013e31823fe8f1. PubMed PMID: 22157621.

Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012 Mar;14(3):315-25. doi: 10.1093/neuonc/nor209. Epub 2011 Dec 12. PubMed PMID: 22156546.

2011

James CD. Stimulating anti-tumor immune response: the problem of regulatory T-cells. Neuro Oncol. 2011 Dec;13(12):1261. doi: 10.1093/neuonc/nor201. PubMed PMID: 22113488.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1. PubMed PMID: 22059152.

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011 Dec 15;17(24):7595-604. doi: 10.1158/1078-0432.CCR-11-1456. Epub 2011 Oct 28. PubMed PMID: 22038996.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24. PubMed PMID: 22025148.

Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27. PubMed PMID: 21954443.

Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1. Epub 2011 Sep 1. PubMed PMID: 21881915.

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011 Aug 19;333(6045):1039-43. doi: 10.1126/science.1203619. PubMed PMID: 21852505.

Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 2012 Jan 2;59(1):193-201. doi: 10.1016/j.neuroimage.2011.07.034. Epub 2011 Jul 23. PubMed PMID: 21807103.

James CD. Evolution of mouse models for studying CNS cancer: a decade of progress. Neuro Oncol. 2011 Jul;13(7):691. doi: 10.1093/neuonc/nor089. PubMed PMID: 21727207.

Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011 Jun;33(6):1284-90. doi: 10.1002/jmri.22563. PubMed PMID: 21590996.

Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr;13(4):384-92. doi: 10.1093/neuonc/noq193. Epub 2011 Feb 11. PubMed PMID: 21317208.

2010

Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 2010 Nov 9;3(147):ra81. doi: 10.1126/scisignal.2001017. PubMed PMID: 21062993.

Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. J Vis Exp. 2010 Aug 16;(42). pii: 1992. doi: 10.3791/1992. PubMed PMID: 20736920.

Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp. 2010 Jul 13;(41). pii: 1986. doi: 10.3791/1986. PubMed PMID: 20644517.

Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther. 2010 Jul;9(7):2131-41. doi: 10.1158/1535-7163.MCT-09-1059. Epub 2010 Jun 29. PubMed PMID: 20587664.

45: James CD. Tumor-initiating cells: an influential paradigm for xenograft research. Neuro Oncol. 2010 Jun;12(6):519. doi: 10.1093/neuonc/noq053. PubMed PMID: 20530515; PubMed Central PMCID: PMC2940644.

Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347-53. doi: 10.1016/j.ijrobp.2010.01.070. Epub 2010 May 25. PubMed PMID: 20510539.

Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010 May 15;24(10):1059-72. doi: 10.1101/gad.1907510. PubMed PMID: 20478998.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049. PubMed PMID: 20385361.

Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010 Apr 15;70(8):3228-38. doi: 10.1158/0008-5472.CAN-09-4559. Epub 2010 Mar 30. PubMed PMID: 20354191.

Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD, VandenBerg SR. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro Oncol. 2010 Apr;12(4):366-76. doi: 10.1093/neuonc/nop033. Epub 2010 Jan 11. PubMed PMID: 20308314.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PubMed PMID: 20129251.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010 Jan 15;70(2):512-9. doi: 10.1158/0008-5472.CAN-09-1851. Epub 2010 Jan 12. PubMed PMID: 20068183.

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010 Jan 15;70(2):453-62. doi: 10.1158/0008-5472.CAN-09-2189. Epub 2010 Jan 12. PubMed PMID: 20068170.

Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, Kurhanewicz J, Vigneron DB, Vandenberg SR, James CD, Nelson SJ. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol. 2010 Feb;12(2):133-44. doi: 10.1093/neuonc/nop043. Epub 2010 Jan 25. PubMed PMID: 20150380.

Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopyCancer Res. 2010 Feb 15;70(4):1296-305. doi: 10.1158/0008-5472.CAN-09-2251. Epub 2010 Feb 9. PubMed PMID: 20145128.

2009

Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang S, James CD, Parsa AT. Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med. 2009 Oct 8;7:84. doi: 10.1186/1479-5876-7-84. Review. PubMed PMID: 19814820.

Silber J, James CD, Hodgson JG. MicroRNAs in gliomas: small regulators of a big problem. Neuromolecular Med. 2009;11(3):208-22. doi: 10.1007/s12017-009-8087-9. Review. PubMed PMID: 19731102.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026. PubMed PMID: 19695438.

Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patientsCancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18. PubMed PMID: 19690143.

Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N. A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol. 2010 Jan;96(2):151-9. doi: 10.1007/s11060-009-9954-9. Epub 2009 Jul 8. PubMed PMID: 19585223.

Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15;15(6):1989-97. doi: 10.1158/1078-0432.CCR-08-2054. Epub 2009 Mar 10. PubMed PMID: 19276270.

James CD, Cavenee WK. Stem cells for treating glioblastoma: how close to reality?Neuro Oncol. 2009 Apr;11(2):101. doi: 10.1215/15228517-2009-016. Epub 2009 Feb 23. PubMed PMID: 19237733.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4. PubMed PMID: 19176518.

Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol. 2009 Oct;11(5):477-87. doi: 10.1215/15228517-2008-113. Epub 2009 Jan 12. PubMed PMID: 19139420.

2008

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcomaJ Clin Oncol. 2009 Feb 1;27(4):579-84. doi: 10.1200/JCO.2008.18.9639. Epub 2008 Dec 15. PubMed PMID: 19075262.

Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 2008 Dec 15;68(24):10034-9. doi: 10.1158/0008-5472.CAN-08-1687. PubMed PMID: 19074867.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15. PubMed PMID: 19011762.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.Neuro Oncol. 2009 Jun;11(3):281-91. doi: 10.1215/15228517-2008-090. Epub 2008 Oct 24. PubMed PMID: 18952979.

Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008 Oct 1;68(19):8094-103. doi: 10.1158/0008-5472.CAN-07-6208. PubMed PMID: 18829568.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14. PubMed PMID: 18577219.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152. PubMed PMID: 18559622.

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008 May 15;14(10):2900-8. doi: 10.1158/1078-0432.CCR-07-1719. Review. PubMed PMID: 18483356.

McAvoy S, Ganapathiraju S, Perez DS, James CD, Smith DI. DMD and IL1RAPL1: two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors. Cytogenet Genome Res. 2007;119(3-4):196-203. doi: 10.1159/000112061. Epub 2008 Feb 1. PubMed PMID: 18253029.

Chi JH, Panner A, Cachola K, Crane CA, Murray J, Pieper RO, James CD, Parsa AT. Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation. J Neurosurg. 2008 Feb;108(2):299-303. doi: 10.3171/JNS/2008/108/2/0299. PubMed PMID: 18240926.

Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A. An orthotopic skull base model of malignant meningioma. Brain Pathol. 2008 Apr;18(2):172-9. Epub 2007 Dec 17. PubMed PMID: 18093250.

Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'neill BP, James CD, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):59-65. Erratum in: Appl Immunohistochem Mol Morphol. 2008 May;16(3):307. David James, Charles [corrected to James, Charles David]. PubMed PMID: 18091318.

2007

Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res. 2007 Dec 1;13(23):7155-65. PubMed PMID: 18056196.

McAvoy S, Zhu Y, Perez DS, James CD, Smith DI. Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. Genes Chromosomes Cancer. 2008 Feb;47(2):165-74. PubMed PMID: 18008369.

McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, Perez DS, Zhu Y, James CD, Smith DI. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res. 2007;118(2-4):260-9. Review. PubMed PMID: 18000379.

Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007 Sep;107(3):610-6. PubMed PMID: 17886562.

Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007 Mar;6(3):1167-74. PubMed PMID: 17363510.

Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL; Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006 Nov;105(5 Suppl):418-24. PubMed PMID: 17328268.

Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomasMol Ther. 2007 Apr;15(4):677-86. Epub 2007 Feb 13. PubMed PMID: 17299404.

Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaJ Clin Oncol. 2007 Jun 1;25(16):2288-94. PubMed PMID: 17538175.

2006

Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006 Dec 15;66(24):11840-50. PubMed PMID: 17178881.

Yung WK, James CD. Mapping the future of Neuro-Oncology. Neuro Oncol. 2007 Jan;9(1):1-2. Epub 2006 Nov 30. PubMed PMID: 17170381.

Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS Sr, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiformeMol Cancer Res. 2006 Oct;4(10):709-14. PubMed PMID: 17050665.

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007 Feb 1;109(3):1228-32. Epub 2006 Jul 13. PubMed PMID: 16840723.

Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71. PubMed PMID: 16609043.

2005

Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia. 2005 Oct;7(10):921-9. PubMed PMID: 16242075.

Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005 Oct;25(20):8809-23. PubMed PMID: 16199861.

Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, Fisher PB. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene. 2005 Nov 17;24(51):7552-66. PubMed PMID: 16044151.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005 Apr;7(2):164-76. PubMed PMID: 15831234.

Park S, James CD. ECop (EGFR-coamplified and overexpressed protein), a novel protein, regulates NF-kappaB transcriptional activity and associated apoptotic response in an IkappaBalpha-dependent manner. Oncogene. 2005 Apr 7;24(15):2495-502. PubMed PMID: 15735698.

Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005 Feb;23(2):209-14. Epub 2005 Jan 30. PubMed PMID: 15685166.

2004

Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin Oncol. 2004 Oct;31(5):595-604. Review. PubMed PMID: 15497113.

Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7. PubMed PMID: 15290895.

Olson JJ, James CD, Lawson D, Hunter S, Tang G, Billingsley J. Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content. Int J Oncol. 2004 Aug;25(2):419-27. PubMed PMID: 15254740.

Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, Dent P. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther. 2004 Aug;3(8):739-51. Epub 2004 Aug 10. PubMed PMID: 15197348.

Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2004 Jan;39(1):29-36. PubMed PMID: 14603439.

2003

Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, Hariharan S, Viskochil D, Perry A. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology. 2003 Nov 25;61(10):1397-400. PubMed PMID: 14638962.

Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci. 2003 May 1;8:e270-80. Review. PubMed PMID: 12700121.

Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003 Apr;121(2):287-95. PubMed PMID: 12694251.

Park S, James CD. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Res. 2003 Feb 1;63(3):723-7. PubMed PMID: 12566319.

Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomasFront Biosci. 2003 Jan 1;8:e1-13. Review. PubMed PMID: 12456322.

2002

Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 2002 Oct 24;21(49):7453-63. Review. PubMed PMID: 12386807.

Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD. p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery. 2002 Nov;51(5):1246-54; discussion 1254-5. PubMed PMID: 12383370.

Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, Wong AJ. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene. 2002 Aug 1;21(33):5038-46. PubMed PMID: 12140754.

Remstein ED, Kurtin PJ, James CD, Wang XY, Meyer RG, Dewald GW. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol. 2002 Jul;161(1):63-71. PubMed PMID: 12107090.

Eley GD, Reiter JL, Pandita A, Park S, Jenkins RB, Maihle NJ, James CD. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro Oncol. 2002 Apr;4(2):86-94. PubMed PMID: 11916499.

2001

Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, James CD. Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104. PubMed PMID: 11706939.

Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics. 2001 Jul;3(3):159-62. PubMed PMID: 11523567.

Thomas C, Ely G, James CD, Jenkins R, Kastan M, Jedlicka A, Burger P, Wharen R. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol. 2001 Jun;101(6):605-15. PubMed PMID: 11515790.

Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56. PubMed PMID: 11504770.

Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001 Aug 1;61(15):5895-904. PubMed PMID: 11479231.

Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001 May 1;12(7):811-21. PubMed PMID: 11339897.

Frederick L, Eley G, Wang XY, James CD. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol. 2000 Jul;2(3):159-63. PubMed PMID: 11302336.

Li J, Perry A, James CD, Gutmann DH. Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology. 2001 Apr 10;56(7):885-90. PubMed PMID: 11294925.

Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001 Mar;158(3):1137-43. PubMed PMID: 11238062.

Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug effluxCancer Res. 2001 Jan 15;61(2):739-48. PubMed PMID: 11212277.

Cai DX, James CD, Scheithauer BW, Couch FJ, Perry A. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol. 2001 Feb;115(2):213-8. PubMed PMID: 11211609.

Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL, Balasubramaniam S, Crossley TD, Magnuson TR, James CD, Maihle NJ. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001 Jan 1;71(1):1-20. Erratum in: Genomics. 2010 Aug;96(2):128. PubMed PMID: 11161793.

2000

Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg. 2000 Dec;102(4):203-209. Review. PubMed PMID: 11154805.

Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, Couch FJ. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res. 2000 Oct 1;60(19):5371-5. PubMed PMID: 11034073.

Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7. PubMed PMID: 10931370.

Biegel JA, Fogelgren B, Zhou JY, James CD, Janss AJ, Allen JC, Zagzag D, Raffel C, Rorke LB. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res. 2000 Jul;6(7):2759-63. PubMed PMID: 10914721.

Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503. PubMed PMID: 10850862.

Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000 Apr;156(4):1183-8. PubMed PMID: 10751343.

Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000 Mar 1;60(5):1383-7. PubMed PMID: 10728703.

Reiter JL, Eley G, James CD, Maihle NJ. Correspondence re: S. Shintani et al., Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res., 59: 4142-4147, 1999. Cancer Res. 2000 Feb 1;60(3):766-7. PubMed PMID: 10676666.

1999

Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutationsClin Cancer Res. 1999 Dec;5(12):4085-90. PubMed PMID: 10632344.

Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 1999 Jul;5(7):1786-92. PubMed PMID: 10430083.

James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol. 1999 Sep;15(3):547-53. PubMed PMID: 10427138.

Alleyne CH Jr, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ. Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol. 1999 Jun;14(6):1111-6. PubMed PMID: 10339666.

Brat DJ, James CD, Jedlicka AE, Connolly DC, Chang E, Castellani RJ, Schmid  M, Schiller M, Carson DA, Burger PC. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol. 1999 May;154(5):1431-8. PubMed PMID: 10329596.

Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999 Apr 1;59(7):1408-11. PubMed PMID: 10197603.

1998

Eley G, Frederick L, Wang XY, Smith DI, James CD. 3' end structure and rearrangements of EGFR in glioblastomas. Genes Chromosomes Cancer. 1998 Nov;23(3):248-54. PubMed PMID: 9790506.

Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol. 1998 Oct;13(4):717-24. PubMed PMID: 9735401.

Khaira P, James CD, Leffak M. Amplification of the translocated c-myc genes in three Burkitt lymphoma cell lines. Gene. 1998 Apr 28;211(1):101-8. PubMed PMID: 9643977.

Wang XY, Smith DI, Liu W, James CD. GBAS, a novel gene encoding a protein with tyrosine phosphorylation sites and a transmembrane domain, is co-amplified with EGFR. Genomics. 1998 May 1;49(3):448-51. PubMed PMID: 9615231.

Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD. Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res. 1998 Jan;4(1):215-22. PubMed PMID: 9516974.

Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res. 1998 Mar 15;26(6):1396-400. PubMed PMID: 9490783.

Wang XY, Smith DI, Frederick L, James CD. Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene. 1998 Jan 15;16(2):191-5. PubMed PMID: 9464536.

1997

Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997 Dec 1;57(23):5254-7. PubMed PMID: 9393744.

Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997 Mar 1;57(5):842-5. PubMed PMID: 9041183.

1996

He J, Olson JJ, Ekstrand AJ, Serbanescu A, Yang J, Offermann MK, James CD. Transfection of IFNalpha in human glioblastoma cells and tumorigenicity in association with induction of PKR and OAS gene expression. J Neurosurg. 1996 Dec;85(6):1085-90. PubMed PMID: 8929499.

Kelker W, Van Dyke DL, Worsham MJ, Christopherson PL, James CD, Conlon MR, Carey TE. Loss of 18q and homozygosity for the DCC locus: possible markers for clinically aggressive squamous cell carcinoma. Anticancer Res. 1996 Jul-Aug;16(4C):2365-72. PubMed PMID: 8816836.

Petronio J, He J, Fults D, Pedone C, James CD, Allen JR. Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications. J Neurosurg. 1996 Jun;84(6):1020-3. PubMed PMID: 8847566.

James CD, Olson JJ. Molecular genetics and molecular biology advances in brain tumors. Curr Opin Oncol. 1996 May;8(3):188-95. Review. PubMed PMID: 8804816.

1995

He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 1995 Nov 1;55(21):4833-6. PubMed PMID: 7585516.

Zhou M, Gu L, James CD, He J, Yeager AM, Smith SD, Findley HW. Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia. Leukemia. 1995 Jul;9(7):1159-61. PubMed PMID: 7630190.

Ekstrand AJ, Liu L, He J, Hamid ML, Longo N, Collins VP, James CD. Altered subcellular location of an activated and tumour-associated epidermal growth factor receptor. Oncogene. 1995 Apr 6;10(7):1455-60. PubMed PMID: 7731699.

Olson JJ, James CD, Krisht A, Barnett D, Hunter S. Analysis of epidermal growth factor receptor gene amplification and alteration in stereotactic biopsies of brain tumors. Neurosurgery. 1995 Apr;36(4):740-6; discussion 747-8. PubMed PMID: 7596505.

Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64. PubMed PMID: 7815080.

1994

He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS 3rd, James CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804-7. PubMed PMID: 7954404.

Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994 Nov;145(5):1175-90. PubMed PMID: 7977648.

He J, Reifenberger G, Liu L, Collins VP, James CD. Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer. 1994 Oct;11(2):91-6. PubMed PMID: 7529554.

Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene. 1994 Aug;9(8):2313-20. PubMed PMID: 8036013.

Ichimura K, Schmidt EE, Yamaguchi N, James CD, Collins VP. A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus. Cancer Res. 1994 Jun 15;54(12):3127-30. PubMed PMID: 8205529.

1993

Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjöld M, Larsson C. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet. 1993 Sep;92(2):169-74. PubMed PMID: 8370584.

James CD, He J, Collins VP, Allalunis-Turner MJ, Day RS 3rd. Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. Cancer Res. 1993 Aug 15;53(16):3674-6. PubMed PMID: 8339274.

Collins VP, James CD. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J. 1993 Jul;7(10):926-30. Review. PubMed PMID: 8344489.

Gerken S, Leppert M, O'Connell P, Cavenee W, James CD, Ballard L, Stauffer D, Elsner T, Plaetke R, Lalouel JM, et al. A genetic linkage map with 29 loci spanning human chromosome 13q. Genomics. 1993 May;16(2):515-9. PubMed PMID: 8100218.

Akoury DA, Seo JJ, James CD, Zaki SR. RT-PCR detection of mRNA recovered from archival glass slide smears. Mod Pathol. 1993 Mar;6(2):195-200. PubMed PMID: 8483891.

1992

Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13. PubMed PMID: 1584765.

James CD, Collins VP. Molecular genetic characterization of CNS tumor oncogenesis. Adv Cancer Res. 1992;58:121-42. Review. PubMed PMID: 1347671.

1991

Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991 Apr 15;51(8):2164-72. PubMed PMID: 2009534.

Cavenee WK, Scrable HJ, James CD. Molecular genetics of human cancer predisposition and progression. Mutat Res. 1991 Apr;247(2):199-202. Review. PubMed PMID: 2011137.

James CD, He J, Carlbom E, Nordenskjold M, Cavenee WK, Collins VP. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res. 1991 Mar 15;51(6):1684-8. PubMed PMID: 1998958.

Houwen RH, Pautler SE, Barwell JA, Arden K, Buchanan JA, James CD, Cavenee WK, Buys CH, Cowell JK, Cox DW. Isolation and regional localization of 25 anonymous DNA probes on a chromosome 13 hybrid panel. Cytogenet Cell Genet. 1991;57(2-3):87-90. Erratum in: Cytogenet Cell Genet 1991;57(4):240. PubMed PMID: 1914527.